---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-022349"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:35:03.334303+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Calidi Biotherapeutics reports Q3 net loss of $5.2M; cash at $10.4M after $6.9M offering

## Summary
- Net loss $5.2M in Q3 2025; net loss attributable to shareholders $10.8M due to non-cash deemed dividend on warrants.
- Basic/diluted EPS loss $2.21 vs $7.75 prior year; cash $10.4M plus $0.2M restricted at Sep 30.
- Gross proceeds of $6.9M from underwritten public offering; total 2025 gross proceeds $23.0M.
- Presented CLD-401 preclinical data at SITC; new Scientific Advisory Board with four experts established.
- RedTail platform expands targeting capabilities and payloads; CLD-401 advancing to IND-enabling studies.

## SEC filing metadata
- accession: 0001493152-25-022349
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315225022349/0001493152-25-022349-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315225022349/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-022349
- JSON: https://secwatch.observer/filing/0001493152-25-022349.json
- Plain text: https://secwatch.observer/filing/0001493152-25-022349.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.